Geode Capital Management LLC Sells 15,876 Shares of Eagle Pharmaceuticals (EGRX)

Geode Capital Management LLC reduced its stake in Eagle Pharmaceuticals (NASDAQ:EGRX) by 17.0% during the 4th quarter, Holdings Channel reports. The firm owned 77,620 shares of the specialty pharmaceutical company’s stock after selling 15,876 shares during the period. Geode Capital Management LLC’s holdings in Eagle Pharmaceuticals were worth $4,146,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. boosted its position in shares of Eagle Pharmaceuticals by 63.9% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 60,716 shares of the specialty pharmaceutical company’s stock worth $3,622,000 after purchasing an additional 23,663 shares during the last quarter. Ameriprise Financial Inc. boosted its position in shares of Eagle Pharmaceuticals by 4.2% in the 3rd quarter. Ameriprise Financial Inc. now owns 138,619 shares of the specialty pharmaceutical company’s stock worth $8,267,000 after purchasing an additional 5,548 shares during the last quarter. Lazard Asset Management LLC boosted its position in shares of Eagle Pharmaceuticals by 4.5% in the 4th quarter. Lazard Asset Management LLC now owns 367,497 shares of the specialty pharmaceutical company’s stock worth $19,631,000 after purchasing an additional 15,824 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Eagle Pharmaceuticals by 7.4% in the 4th quarter. Victory Capital Management Inc. now owns 1,050,167 shares of the specialty pharmaceutical company’s stock worth $56,101,000 after purchasing an additional 72,217 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in shares of Eagle Pharmaceuticals by 35.5% in the 3rd quarter. Wells Fargo & Company MN now owns 21,506 shares of the specialty pharmaceutical company’s stock worth $1,283,000 after purchasing an additional 5,640 shares during the last quarter.

In other Eagle Pharmaceuticals news, Director Sander A. Flaum sold 2,340 shares of Eagle Pharmaceuticals stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $53.94, for a total transaction of $126,219.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 19.50% of the company’s stock.

Several research firms have recently issued reports on EGRX. BidaskClub lowered Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 18th. ValuEngine lowered Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. Mizuho reiterated a “sell” rating and set a $37.00 target price on shares of Eagle Pharmaceuticals in a report on Monday, February 26th. Zacks Investment Research lowered Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 9th. Finally, Piper Jaffray reiterated a “buy” rating and set a $79.00 target price on shares of Eagle Pharmaceuticals in a report on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the stock. Eagle Pharmaceuticals has a consensus rating of “Hold” and an average target price of $63.33.

EGRX stock opened at $55.16 on Friday. The company has a debt-to-equity ratio of 0.24, a quick ratio of 3.88 and a current ratio of 3.99. The stock has a market cap of $798.98, a price-to-earnings ratio of 16.37 and a beta of 1.38. Eagle Pharmaceuticals has a 1-year low of $45.05 and a 1-year high of $97.15.

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its earnings results on Monday, February 26th. The specialty pharmaceutical company reported $0.84 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.00 by ($0.16). The business had revenue of $46.80 million for the quarter, compared to the consensus estimate of $53.65 million. Eagle Pharmaceuticals had a return on equity of 34.16% and a net margin of 21.94%. The business’s revenue was down 42.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.52 earnings per share. analysts predict that Eagle Pharmaceuticals will post 2.44 earnings per share for the current year.

WARNING: “Geode Capital Management LLC Sells 15,876 Shares of Eagle Pharmaceuticals (EGRX)” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3372765/geode-capital-management-llc-sells-15876-shares-of-eagle-pharmaceuticals-egrx.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Want to see what other hedge funds are holding EGRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eagle Pharmaceuticals (NASDAQ:EGRX).

Institutional Ownership by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Jingtum Tech   Trading 27% Lower  This Week
Jingtum Tech Trading 27% Lower This Week
Steem Dollars One Day Trading Volume Tops $1.27 Million
Steem Dollars One Day Trading Volume Tops $1.27 Million
World Fuel Services Corp  Plans Quarterly Dividend of $0.06
World Fuel Services Corp Plans Quarterly Dividend of $0.06
Recent Analysts’ Ratings Updates for Brookline Bancorp
Recent Analysts’ Ratings Updates for Brookline Bancorp
Canadian Imperial Bank of Commerce  Given New C$138.00 Price Target at Barclays
Canadian Imperial Bank of Commerce Given New C$138.00 Price Target at Barclays
Quality Systems  Price Target Increased to $22.00 by Analysts at Piper Jaffray Companies
Quality Systems Price Target Increased to $22.00 by Analysts at Piper Jaffray Companies


© 2006-2018 Ticker Report. Google+.